FindTrial
Sign In

Efficacy of Recombinant Human Bone Morphogenetic Protein - 2 in Promoting Interbody Fusion for Degenerative Lumbar Spondylolisthesis in Type 2 Diabetes Mellitus Patients: A Retrospective Cohort Study

Efficacy of Recombinant Human Bone Morphogenetic Protein - 2 in Promoting Interbody Fusion for Degenerative Lumbar Spondylolisthesis in Type 2 Diabetes Mellitus Patients: A Retrospective Cohort Study

Status
Active, not recruiting
Phases
Unknown
Study type
Observational
Source
ChiCTR
Registry ID
ChiCTR2600121325
Enrollment
Unknown
Registered
2026-03-30
Start date
2026-04-01
Completion date
Unknown
Last updated
2026-04-14

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Lumbar Spondylolisthesis

Interventions

Fusion group:None
Pseudarthrosis group:None

Sponsors

Tongji Hospital Affiliated To Tongji University
Lead Sponsor

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria: 1. Diagnosed with lumbar spondylolisthesis and unresponsive to conservative treatment; 2. Underwent TLIF surgery; postoperative follow-up period >= 6 months; 3. Possession of complete lumbar CT imaging at final follow-up to assess fusion status.

Exclusion criteria

Exclusion criteria: 1. Spinal tumors, tuberculosis, or severe infections; 2. History of lumbar spine surgery (revision surgery); 3. Missing clinical or imaging data; 4. Loss to follow-up or absence of CT scan at last follow-up.

Design outcomes

Primary

MeasureTime frame
Postoperative Fusion Score for Lumbar Interbody Fusion;—

Countries

China

Contacts

Public ContactLiming Cheng

Tongji Hospital Affiliated To Tongji University

limingcheng@tongji.edu.cn+86 137 0195 9550

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Apr 17, 2026